US 12168692
Antibodies targeting CCR2
granted A61KA61K2039/505
Quick answer
US patent 12168692 (Antibodies targeting CCR2) held by Granite Bio AG expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Granite Bio AG
- Grant date
- Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505